A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Access Programs

Disease Information

Descriptive Information
Brief Title † A Phase 0 Study of AZD1775 in Recurrent GBM Patients
Official Title † A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration
Brief Summary This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug. The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.
Detailed Description Patients will be administered one dose of AZD1775 prior to surgical resection of their tumor. There will be 2 portions of this trial, referred to as Part 1 and Part 2. Part 1 will involve a dose escalation strategy where 3 separate doses (100, 200, and 400mg) will be evaluated. Each dose cohort will involve 4 patients. Surgery, with tissue harvest for determination of both tissue drug level and biomarker evaluation, will occur at 8 hrs post drug administration. Part 2 will determine the potential tumor drug level and PD effects at various time intervals after drug administration of a single select drug dose. Currently, we are planning to use a dose (200 mg) that has been deemed safe when used in combination with cytotoxic therapy. However, if results from Part 1 suggest an alternate dose may be preferable, we will consider using that alternate dose in Part 2. Dosing will be followed by surgical resection at 2-4 hrs and at 22-26 hrs post dose.
Study Phase Phase 0
Study Type † Interventional
Study Design † Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary Outcome Measure † Plasma concentration of AZD1775 following single dose of AZD1775
Secondary Outcome Measure † Degree of CDC2 (Tyr15) phosphorylation in tissue
Condition † Glioblastoma GBM
Intervention † BiologicalAZD1775
Study Arms / Comparison Groups AZD1775 Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Biological
Estimated Enrollment † 20
Start Date † July 2014
Completion Date May 2018
Primary Completion Date December 2017
Eligibility Criteria † Inclusion Criteria: 1. Patients with 1 prior resection of histologically-diagnosed de novo GBM 2. Patient must have MRI evidence of disease recurrence 3. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status ≤2 4. Patients ≥ 18 years of age 5. Adequate hematologic, renal, and hepatic function 6. Patients must not have co-morbid condition(s) that, at the opinion of the investigator, prevent safe surgical treatment 7. Patients must not have active infection or fever > 38.5°C 8. Patients must not be pregnant or nursing 9. Patients must have archival tumor tissue block available for research use 10. Ability to understand and the willingness to sign a written informed consent document. 11. Patient has voluntarily agreed to participate by giving written informed consent. Exclusion Criteria: 1. Less than 18 years of age 2. Diagnosis of anything other than first-recurrence GBM 3. GBM tissue from first-resection not available 4. Previous treatment with AZD1775 5. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 6. Patient has known hypersensitivity to the components of potential study therapy or its analogs. 7. Patient has had prescription or non-prescription drugs or other products known to be metabolized by cytochrome P450 3A4 (CYP3A4), or to inhibit or induce CYP3A4, which cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication (inhibitors generally for 5 half-lives). Medications of particular concern are the following inhibitors of CYP3A4: azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole), macrolide antibiotics (erythromycin, clarithromycin), cimetidine, HIV protease inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin, barbiturates and rifampicin. Substrates of CYP3A4 include statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and cisapride. CYP3A4. 8. Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate. 9. Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 10. Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse. 11. Patients expecting to reproduce within the projected duration of the study (estimated to be 1 year), and women who are pregnant or breastfeeding. 12. Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS). 13. Patient has known history of Hepatitis B or C. 14. Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible. 15. Patient has a clinical history suggestive of Li-Fraumeni Syndrome.
Gender Both
Ages 18 Years - N/A
Accepts Healthy Volunteers No
Contacts ††
Location Countries † United States
Administrative Information
NCT ID † NCT02207010
Organization ID BBTRC 001
Secondary IDs ††
Responsible Party Sponsor
Study Sponsor † St. Joseph's Hospital and Medical Center, Phoenix
Collaborators †† The Ben & Catherine Ivy Foundation
Investigators † Principal Investigator: Nader Sanai, MD, Barrow Neurological Institute at St.Joseph's Hospital Medical Center
Information Provided By
Verification Date January 2017
First Received Date † July 28, 2014
Last Updated Date January 4, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma
Free Newsletter